Document is current
Any future updates will be listed below
-
Authors
Scheiter, Alexander https://orcid.org/0000-0001-6734-261X
Mellin, Simon
Keil, Felix https://orcid.org/0000-0002-0651-5916
Meier, Johannes https://orcid.org/0000-0003-0482-9951
Heudobler, Daniel
Brummer, Christina
Einhell, Sabine
Zwicker, Benjamin
Wutzlhofer, Elena
Hierl, Frederik
Klemm, Sophie
Lüftl, Elena
Schneider, Tom
Perl, Markus
Klier-Richter, Margit
Immel, Alexander
Kaltofen, Till https://orcid.org/0000-0003-1137-211X
Grube, Matthias
Bumes, Elisabeth https://orcid.org/0000-0001-6915-3206
Seitz, Stephan
Schulz, Christian
Haferkamp, Sebastian
Drexler, Konstantin
Troeger, Anja
Steger, Felix
Schlosser-Hupf, Sophie
Tews, Hauke Christian
Kandulski, Arne https://orcid.org/0009-0005-9065-8395
Wohlfart, Kristina
Erber, Ramona
Schönbuchner, Ines
Lessel, Davor
Schnabel, Marco J.
Sedlmeier, Anja M.
Klinkhammer-Schalke, Monika
Maurer, Julia
Calvisi, Diego F.
Pukrop, Tobias
Kaiser, Ulrich
Hirsch, Daniela https://orcid.org/0000-0001-8883-922X
Dietmaier, Wolfgang
Evert, Matthias
Lüke, Florian
Utpatel, Kirsten
-
Funding
Funding for this research was provided by:
BZKF (MTB QUANTIFY)
Universitätsklinikum Regensburg
- License Information
-
More Information
Article History
Received: 2 May 2025
Accepted: 8 January 2026
First Online: 14 January 2026
Declarations
:
: The prospective observational study conducted by the Molecular Tumor Board (MTB) of the Comprehensive Cancer Center Ostbayern (CCCO) adhered to the principles of the Declaration of Helsinki and received approval from the Ethics Committee of the University of Regensburg (protocol code 20–1682-101). Written informed consent was obtained from all patients included in the study.
: Written consent for publication was obtained from all patients included in the MTB observational study.
: Alexander Scheiter (AS1): Travel/expenses: Roche.Till Kaltofen (TK): Travel/expenses: Roche.Stephan Seitz (SS1): Honoraria: AstraZeneca, lovis, GE, Gilead, GSK, MSD, Novartis, Pfizer, Roche, and Lilly.Marco Schnabel (MS): Advisory board: Bayer, Bristol Myers Squibb, Ipsen, Merck & Co, Pfizer. Honoraria: Bayer, Bristol Myers Squibb, GlaxoSmithKline, Ipsen, Medac, Merck, MSD, Pfizer. Travel/accommodation/expenses: Apogepha, Janssen, Ipsen, Pfizer. Institutional grants/contracts: Ipsen, Janssen, AstraZeneca, QED Therapeutics Inc.Ramona Erber (RE): Honoraria: Roche, Eisai, Pfizer, BioNTech, Veracyte (PROCURE), Diaceutics, Mindpeak, AstraZeneca, MEDAC, Lilly and Novartis. Research grants: AstraZeneca, Biocartis, Biontech, Cepheid, Gilead, Illumina, Nanostring Technologies, Mindpeak, MSD, Novartis, Owkin, palleos healthcare, Owkin, Qiagen, QuIP GmbH, Roche, Sanofi, Stratifyer, Zytovision. Daniela Hirsch (DH2): Lecture fees: AstraZeneca.Sebastian Haferkamp (SH): Honoraria: BMS, Pierre Fabre, MSD, Novartis.Kirsten Utpatel (KU): Advisory Board: BMS. Lecture fees: Roche, Honoraria: Roche, BMS, Stemline, MSD, Lilly, AMGEN.Arne Kandulski (AK): Advisory Board: BMS, Roche Pharma AG, Eisai GmbH, Bayer Pharma, AbbVie Germany, Janssen-Cilag, Boston-Scientific Corp.; Honoraria: Roche Pharma AG, Eisai GmbH, Bayer Pharma, Boston Scientific Corp., Fujifilm Deutschland, Janssen-Cilag, AbbVie Germany.
